Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -10 of 905
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
5/31/2007
 
First Published:
7/1/1999
1.
Phase II/III Randomized Study of Paclitaxel and Carboplatin With or Without SCH 58500 in Patients with Newly Diagnosed Stage III Ovarian Epithelial or Primary Peritoneal Cancer With No Greater Than 2 cm Residual Disease Following Surgery (Summary Last Modified 07/2001)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Completed
18 and over
Pharmaceutical / Industry
SPRI-C/I98-102
SPRI-C98-102, NCI-V99-1544, NCT00003880
Last Modified:
6/20/2008
 
First Published:
9/1/2000
2.
Phase II/III Randomized Study of Paclitaxel and Carboplatin With or Without BMS-275291 in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Closed
18 and over
Pharmaceutical / Industry
CAN-NCIC-BR18
BMS-CA161-003, NCT00006229, BR18
Last Modified:
3/18/2008
 
First Published:
4/1/2001
3.
Phase II/III Randomized Study of Gemcitabine and Carboplatin Versus Methotrexate, Carboplatin, and Vinblastine in Previously Untreated Patients With Transitional Cell Cancer of the Urothelium Who are Ineligible for Cisplatin-Based Chemotherapy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Closed
18 and over
Other
EORTC-GU-30986
NCT00014274
Last Modified:
6/3/2008
 
First Published:
7/1/2001
4.
Phase II/III Randomized Study of Paclitaxel and Carboplatin With or Without Bevacizumab in Patients With Advanced, Metastatic, or Recurrent Non-Squamous Cell Non-Small Cell Lung Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Closed
18 and over
NCI
ECOG-4599
CALGB-E4599, E4599, NCT00021060
Last Modified:
5/23/2007
5.
Phase II/III Chemotherapy with MVP (MITO/VBL/CACP) vs CHIP vs CBDCA vs VBL/CACP vs MVP-CAMP (MITO/VBL/CACP/CTX/ADR/MTX/PCB) in Patients with Metastatic (Stage III) non-Small Cell Bronchogenic Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Completed
no age specified
NCI
EST-1583
6.
Phase II/III Comparison of the Platinum Compounds CBDCA vs CHIP vs CACP for Recurrent or Metastatic Epidermoid Carcinoma of the Head and Neck
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Closed
no age specified
UMCC-8223
Last Modified:
8/10/2007
7.
Phase III Master Protocol for Randomized Comparison of Single-agent Chemotherapy vs Standard Therapy with CAF (CTX/DOX/5-FU) in Previously Untreated Patients with Stage IV Breast Carcinoma --- Amonafide and Other Phase II Agents
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Completed
16 to physiologic 70
NCI
CLB-8642
CALGB-8642
Last Modified:
4/12/2007
8.
Phase II Evaluation of IPP, CBDCA, CHIP, and epi-ADR as Single Agents Prior to Phase III Randomized Comparison of CECA (CACP/VP-16/CTX/ADR) vs High-Dose CACP/VP-16/CTX/ADR in Children Aged at Least 365 Days with Previously Untreated Stage D Neuroblastoma and Phase III Multimodal Treatment of Stage C Disease
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Completed
1 to 21
NCI
POG-8741/42
POG-8741, POG-8742
Last Modified:
10/24/2008
9.
Phase II/III Randomized Comparison of Consolidation with Intensive Chemotherapy Using CDDP/VP-16/DOX/IFF vs Myeloablative Chemoradiotherapy and Autologous Marrow Rescue and of Continuation Therapy with Isotretinoin vs No Further Therapy in High-Risk Neuroblastoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Closed
0 to 18
NCI
CCG-3891
Last Modified:
5/20/2008
 
First Published:
10/21/2005
10.
Phase II/III Randomized Study of Paclitaxel and Carboplatin With Versus Without AZD2171 in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Closed
18 and over
Other, Pharmaceutical / Industry
CAN-NCIC-BR24
ZENECA-CAN-NCIC-BR24, NCT00245154, BR24, FHCRC-6107, UWCC-UW 6107, UWCC- 06-2707-H/B
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute